Stocks Health care SGHT
NASDAQ · Health careSight Sciences, Inc. (SGHT)
Sight Sciences, Inc. brought in $88.4M of revenue over the twelve months to September 30, 2026, up 16.2% from a year earlier. It posted a net loss of $28.4M. In fiscal 2025 capital spending exceeded operating cash flow by $29.9M. At September 30, 2026 it held $77.4M in cash against $42.4M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 4, 2026.
Key facts about Sight Sciences, Inc.
- Net worth
- Sight Sciences, Inc. has a market value (market cap) of $592.2M at the latest share price, and shareholders' equity of $49.1M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $77.4M (-3.1% year on year), with a net loss of $38.4M. Over the 12 months to September 30, 2026: revenue $88.4M, net loss $28.4M.
- Cash flow
- In fiscal 2025 operations used $29.7M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 4, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Sight Sciences, Inc.'s next report is expected around January 12, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Sight Sciences, Inc. does
Sight Sciences, Inc. is registered with the SEC under industry code SIC 3841 (Surgical & Medical Instruments & Apparatus). Its shares trade on NASDAQ under the ticker SGHT.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $77.4M | -$38.4M | -$0.74 | -$29.9M |
| 2024 | $79.9M | -$51.5M | -$1.03 | -$22.7M |
| 2023 | $81.1M | -$55.5M | -$1.14 | -$48M |
| 2022 | $71.3M | -$86.2M | -$1.80 | -$76.9M |
| 2021 | $49M | -$63M | -$2.36 | -$53.4M |
| 2021 | $27.6M | -$34.7M | -$3.71 | -$33.1M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where SGHT ranks in Health care
Latest SEC filings
What Sight Sciences, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 4, 2026Quarterly report 10-Q · period to September 30, 2026Revenue rose 25% to $24.9M versus the same quarter last year; diluted EPS -$0.12 versus -$0.16.
- November 4, 2026
- August 10, 2026
- August 5, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 20% to $23.4M versus the same quarter last year; diluted EPS -$0.08 versus -$0.23.
- August 5, 2026
- June 5, 2026
- May 29, 2026
- May 6, 2026Quarterly report 10-Q · period to March 31, 2026Revenue rose 13% to $19.7M versus the same quarter last year; diluted EPS -$0.24 versus -$0.28.
- May 6, 2026
- April 23, 2026
Insider trades
What the people running Sight Sciences, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $652.8K worth of shares in the last 90 days and bought none on the open market. All of the selling was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| October 2, 2026 | Rodberg JamesChief Financial Officer | Soldpre-planned (10b5-1) | 7,208 | $63.8K |
| October 2, 2026 | Bauerlein AlisonChief Operating Officer | Soldpre-planned (10b5-1) | 25,260 | $223.6K |
| October 2, 2026 | Taylor BrentonEVP, Operations & R&D | Soldpre-planned (10b5-1) | 2,988 | $26.5K |
| October 1, 2026 | Badawi PaulPresident and CEO, Director, 10% owner | Soldpre-planned (10b5-1) | 29,653 | $268.3K |
| October 1, 2026 | Badawi DavidChief Technology Officer, Director | Soldpre-planned (10b5-1) | 7,797 | $70.6K |
| August 10, 2026 | Rashid KashifChief Legal Officer | Received as pay | 181,818 | - |
| July 6, 2026 | Badawi DavidChief Technology Officer, Director | Soldpre-planned (10b5-1) | 7,418 | $40.9K |
| July 6, 2026 | Hayden Jeremy B.Chief Legal Officer | Soldpre-planned (10b5-1) | 12,733 | $70.1K |
Who owns SGHT
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Staffan Encrantz13D, may seek influence with 2 related filers | 13.1% | March 13, 2025 |
| Long Focus Capital Management, LLC13G, passive with 1 related filers | 6% | May 15, 2025 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 112 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Long Focus Capital Management, LLC | 3,844,100 | +250,000 |
| BlackRock, Inc. | 3,083,108 | +251,176 |
| Americana Partners, LLC | 1,679,069 | +52 |
| Pathstone Holdings, LLC | 1,678,980 | -718,352 |
| Vanguard Capital Management LLC | 1,573,815 | +121,125 |
| Geode Capital Management, LLC | 958,565 | +43,121 |
| State Street Corp | 835,452 | +424 |
| B Group, Inc. | 970,000 | 0 |
| Aqr Capital Management LLC | 397,558 | +259,041 |
| Dimensional Fund Advisors LP | 383,512 | +41,831 |
| Qube Research & Technologies Ltd | 362,703 | -134,805 |
| Northern Trust Corp | 343,582 | +11,273 |
| Jacobs Levy Equity Management, Inc | 338,441 | +10,529 |
| D. E. Shaw & Co., Inc. | 279,949 | -31,425 |
| Charles Schwab Investment Management Inc | 275,553 | -3,036 |
| Vanguard Portfolio Management LLC | 272,485 | +23,402 |
| Panagora Asset Management Inc | 262,528 | +68,361 |
| Vanguard Fiduciary Trust Co | 256,078 | +15,153 |
| Squarepoint Ops LLC | 218,108 | -113,646 |
| Citadel Advisors LLC | 216,307 | +81,004 |
Insiders
12 insiders reported holding 11,655,046 shares in total, about $125.3M at the last price.
| Holder | Shares |
|---|---|
| Badawi PaulPresident and CEO, Director, 10% owner | 6,092,819 |
| Badawi DavidChief Technology Officer, Director | 1,975,075 |
| Encrantz StaffanDirector, 10% owner | 1,434,283 |
| Bauerlein AlisonChief Operating Officer | 639,449 |
| Hayden Jeremy B.Chief Legal Officer | 357,037 |
| Taylor BrentonEVP, Operations & R&D | 261,990 |
| Rodberg JamesChief Financial Officer | 216,829 |
| Zurbay DonaldDirector | 193,613 |
| Rashid KashifChief Legal Officer | 181,818 |
| Burbach Gerhard FDirector | 123,207 |
Questions about SGHT
What does Sight Sciences, Inc. do?
Sight Sciences, Inc. is a company in the Health care sector, listed on NASDAQ as SGHT. Its shares trade on NASDAQ under the ticker SGHT.
What is Sight Sciences, Inc.'s net worth?
Sight Sciences, Inc. has a market value (market cap) of $592.2M at the latest share price, and shareholders' equity of $49.1M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Sight Sciences, Inc. profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $28.4M on revenue of $88.4M.
How much revenue does Sight Sciences, Inc. make?
Over the twelve months to September 30, 2026 Sight Sciences, Inc. reported revenue of $88.4M. That is 16.2% more than a year earlier.
When did Sight Sciences, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 4, 2026. It covers the period to September 30, 2026. Its newest filing of any kind is the planned insider sale from November 5, 2026.
When is Sight Sciences, Inc.'s next earnings report?
Sight Sciences, Inc.'s next report is expected around January 12, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare SGHT with
Follow SGHT
Get an email when Sight Sciences, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Sight Sciences, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.